Takeda Pharmaceutical (TAK) Long-Term Debt Repayments (2020 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Long-Term Debt Repayments of -$156847.6 for Q2 2026, up 99.98% year-over-year from -$78430.9 in Q2 2025, and up 99.97% quarter-over-quarter from -$478.4 million in Q1 2026.
Takeda Pharmaceutical (TAK) Long-Term Debt Repayments (2020 - 2026) Analysis & Trends
Takeda Pharmaceutical's Long-Term Debt Repayments history runs 7 years deep, the most recent figure standing at -$156847.6 for Q2 2026.
- In Q2 2026, Long-Term Debt Repayments rose 99.98% year-over-year to -$156847.6; the TTM figure through Jun 2026 stood at -$479.3 million (up 94.81% YoY), while the FY2026 annual figure was -$1.3 billion, up 84.65% from the prior year.
- Long-Term Debt Repayments for Q2 2026 stood at -$156847.6, up from -$478.4 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was -$149451.7 in Q4 2025, with the low at -$3.5 billion in Q1 2025.
- The 5-year median for Long-Term Debt Repayments is -$536.6 million (2023), against an average of -$909.8 million.
- Peak annual rise in Long-Term Debt Repayments reached 100.0% in 2025, while the deepest fall reached 620894.46% in 2025.
- Takeda Pharmaceutical's Long-Term Debt Repayments stood at -$1.8 billion in 2022, then soared by 71.96% to -$505.5 million in 2023, then sank by 550.65% to -$3.3 billion in 2024, then soared by 100.0% to -$149451.7 in 2025, then dropped by 4.95% to -$156847.6 in 2026.
- Business Quant data shows TAK's Long-Term Debt Repayments at -$156847.6 in Q2 2026, -$478.4 million in Q1 2026, and -$149451.7 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -156,847.56 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -156,847.56 |
| Jun 30, 2026 | -156,847.56 |
| Mar 31, 2026 | -478.39 Mn |
| Mar 31, 2026 | -478.39 Mn |
| Dec 31, 2025 | -149,451.71 |
| Dec 31, 2025 | -149,451.71 |
| Sep 30, 2025 | -604,021.56 |
| Sep 30, 2025 | -604,021.56 |
| Jun 30, 2025 | -865.93 Mn |
| Jun 30, 2025 | -865.93 Mn |
| Mar 31, 2025 | -3.52 Bn |
| Mar 31, 2025 | -3.52 Bn |
| Dec 31, 2024 | -3.29 Bn |
| Dec 31, 2024 | -3.29 Bn |
| Sep 30, 2024 | -1.57 Bn |
| Sep 30, 2024 | -1.57 Bn |
| Jun 30, 2024 | -321.90 Mn |
| Jun 30, 2024 | -321.90 Mn |
| Mar 31, 2024 | -566,816.40 |
| Mar 31, 2024 | -566,816.40 |